Ivermectin, a drug commonly used to treat parasitic infections in humans and animals, has been found to show promising results in combating not only COVID-19 but also certain types of cancer. Research studies have shown that ivermectin has antiviral properties that can inhibit the replication of the SARS-CoV-2 virus, which causes COVID-19. It works by blocking the viral entry and replication process, thus reducing the severity of the infection and potentially preventing the transmission of the virus to others.
In addition to its antiviral properties, ivermectin has also demonstrated potential in the treatment of cancer. Studies have shown that ivermectin can inhibit the growth of cancer cells by inducing cell cycle arrest and apoptosis, leading to the death of cancer cells. This makes ivermectin a promising candidate for use in cancer therapy, either alone or in combination with other anticancer drugs.
While more research is needed to fully understand the effectiveness of ivermectin against COVID-19 and cancer, the early findings are encouraging.
Coincidently, Ivermectin has recently become unavailable in Serbia.
The absence of Ivermectin in Serbia has raised questions about the country's ability to effectively manage and treat parasitic infections in both humans and animals.
Alternatively, sweet wormwood, also known as Artemisia annua, is emerging as a promising alternative to ivermectin for treating various parasitic infections. This herb contains a compound called artemisinin, which has been found to exhibit anti-parasitic properties. Moreover, sweet wormwood has been shown to be effective against a variety of parasites, including those that are resistant to conventional treatments like ivermectin.
Additionally, sweet wormwood has minimal side effects and is readily available in many parts of the world including Serbia. As interest in alternative therapies continues to grow, sweet wormwood may prove to be a valuable option for combating parasitic infections in both humans and animals.
응답 (0)